• We observed a high prevalence (70%) of TP53 mutations in 17p-deleted patients
Introduction
Deletion of the 17p13 locus, which harbors the tumour suppressor gene TP53, has long been known to define the group of chronic lymphocytic leukemia (CLL) patients with the poorest clinical outcome. Furthermore, over 70% of CLL patients with 17p-deletion harbor TP53 mutations on the remaining allele 1, 2 . However, recent studies report that 3-5% of CLL patients may carry TP53 mutations without 17p-deletion [3] [4] [5] [6] and that TP53 mutation status can predict poor survival in CLL.
Aim
Since most earlier studies reporting TP53 mutation frequencies in CLL focused on cohorts collected via referral centres, we aim to investigate the frequency of TP53 mutation within a Scandinavian population-based cohort, in order to gain a more representative prevalence of TP53 mutation in CLL at diagnosis. Of the three patients carrying TP53 mutations only, 2 were still alive more than 9 years after diagnosis and one remained untreated. Notably all 3 patients carried IGHV mutated genes. Patient cohort
Results 1 Results 2
All samples were sourced from the Scandinavian Lymphoma Etiology (SCALE) project, a population-based case-control study of newly diagnosed lymphoma patients and controls. Samples were obtained from 650 CLL patients located throughout Denmark and Sweden. Comprehensive clinical data was also collected for all patients. Subsequently, 370 cases were run on Affymetrix (250K), SNP array gaining information on recurrent genomic aberrations.
Methods
• The TP53 exons 4-8 were amplified in 268 patients.Three different primer sets were used to cover all 5 exons. All amplicons were then direct sequenced.
• Vector NTI Advance (version 10.3.1), BioEdit Sequence Alignment Editor (Version 7.0.5.3) the GenBank data library were used to analyse and align sequences.
• All mutations identified were reconfirmed by sequencing of a second PCR product.
• Overall survival and time to treatment were estimated by the Kaplan-Meier method using Statistica 9.0 software.
We observed a significant decrease in the overall survival and time to treatment of patients with TP53 mutations and 17p deletion (p=0.00002 and p=0.0128 respectively). 
P=0.0128
The TP53 gene was analysed for the presence of mutations in 268 newly diagnosed CLL patients by direct sequencing of exons 4-8.The results are presented in Table 2 . 
